Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Safety and Efficacy of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Insulin glargine versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in combination with metformin in subjects with Type 2 Diabetes.

Inclusion Criteria:

• Type 2 diabetes
• Body mass index equal to or lesser than 35.0 kg/m2
• Currently treated with oral hypoglycaemic drug

Exclusion Criteria:

• Known hypoglycaemia unawareness or recurrent major hypoglycaemia as judged by the Investigator
• Any condition that the Investigator and/or the Sponsor feel would interfere with trial participation or evaluation of results